GlassScriptPhysician profile
Yamilee Cabrol
NPI 1407514672
$2,926.44
in general payments reported to CMS, 2019-2025
25 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,931 · 2023: $560 · 2024: $323 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $459.77 | 2022-2023 | Rayaldee |
| Lilly USA, LLC | $273.14 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $270.64 | 2022-2024 | Rybelsus, Ozempic |
| Fresenius USA Marketing, INC. | $240.03 | 2022-2023 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $203.33 | 2022 | |
| Aurinia Pharma U.S., INC. | $186.08 | 2022-2023 | Lupkynis |
| Calliditas Therapeutics US INC. | $159.88 | 2022-2023 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $149.41 | 2022 | |
| Horizon Therapeutics Plc | $148.72 | 2022 | |
| Mallinckrodt Hospital Products INC. | $132.71 | 2022-2023 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.80 | 2023 | Jardiance |
| Amgen INC. | $94.45 | 2022-2025 | Repatha, Otezla, Repatha |
| Vifor Pharma, INC. | $93.76 | 2022-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $66.09 | 2022-2023 | Jynarque |
| Daiichi Sankyo INC. | $60.53 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $47.57 | 2022-2023 | Auryxia |
| Ani Pharmaceuticals, INC. | $42.06 | 2022 | |
| Janssen Biotech, INC. | $31.92 | 2023-2024 | Erleada |
| Alexion Pharmaceuticals, INC. | $27.78 | 2022 | |
| Glaxosmithkline, LLC. | $27.53 | 2024 | Trelegy Ellipta |
| Ultragenyx Pharmaceutical INC. | $22.34 | 2023 | Crysvita |
| Abbvie INC. | $21.31 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.44 | 2022 | |
| Urovant Sciences INC | $16.84 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.31 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yamilee Cabrol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.